Low incidence of anti-interferon-alpha antibodies in patients treated with interferon-alpha-2a for AIDS-associated Kaposi's sarcoma

R. De Wit; P. J.M. Bakker; S. A. Danner; J. Goudsmit; K. H.N. Veenhof

doi:10.1177/095646249000100405

Low incidence of anti-interferon-alpha antibodies in patients treated with interferon-alpha-2a for AIDS-associated Kaposi's sarcoma

R. De Wit, P. J.M. Bakker, S. A. Danner, J. Goudsmit, K. H.N. Veenhof

Internal medicine

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Anti-interferon (IFN)-alpha antibodies were determined in the serum of 28 patients treated with high-dose human recombinant IFN-alpha-2a for AIDS-associated Kaposi's sarcoma. After a median treatment duration of 3 months, 3 patients developed anti-IFN-alpha antibodies, of whom 2 showed a long lasting tumour response despite the development of these antibodies. None of 3 patients with tumour progression after an initial treatment response had developed IFN-alpha neutralizing antibodies. In conclusion, a low incidence of anti-IFN-alpha antibodies during treatment with high dose IFN-alpha was found, but the appearance had no detrimental effect on the duration of tumour responses in a small number of patients.

Original language	English
Pages (from-to)	256-258
Number of pages	3
Journal	International Journal of STD and AIDS
Volume	1
Issue number	4
DOIs	https://doi.org/10.1177/095646249000100405
Publication status	Published - 1990

Access to Document

10.1177/095646249000100405

Link to publication in Scopus

Cite this

@article{8a00ff8007c94d1687ff92a97b205575,

title = "Low incidence of anti-interferon-alpha antibodies in patients treated with interferon-alpha-2a for AIDS-associated Kaposi's sarcoma",

abstract = "Anti-interferon (IFN)-alpha antibodies were determined in the serum of 28 patients treated with high-dose human recombinant IFN-alpha-2a for AIDS-associated Kaposi's sarcoma. After a median treatment duration of 3 months, 3 patients developed anti-IFN-alpha antibodies, of whom 2 showed a long lasting tumour response despite the development of these antibodies. None of 3 patients with tumour progression after an initial treatment response had developed IFN-alpha neutralizing antibodies. In conclusion, a low incidence of anti-IFN-alpha antibodies during treatment with high dose IFN-alpha was found, but the appearance had no detrimental effect on the duration of tumour responses in a small number of patients.",

author = "{De Wit}, R. and Bakker, {P. J.M.} and Danner, {S. A.} and J. Goudsmit and Veenhof, {K. H.N.}",

year = "1990",

doi = "10.1177/095646249000100405",

language = "English",

volume = "1",

pages = "256--258",

journal = "International Journal of STD and AIDS",

issn = "0956-4624",

publisher = "SAGE Publications Ltd",

number = "4",

}

TY - JOUR

T1 - Low incidence of anti-interferon-alpha antibodies in patients treated with interferon-alpha-2a for AIDS-associated Kaposi's sarcoma

AU - De Wit, R.

AU - Bakker, P. J.M.

AU - Danner, S. A.

AU - Goudsmit, J.

AU - Veenhof, K. H.N.

PY - 1990

Y1 - 1990

N2 - Anti-interferon (IFN)-alpha antibodies were determined in the serum of 28 patients treated with high-dose human recombinant IFN-alpha-2a for AIDS-associated Kaposi's sarcoma. After a median treatment duration of 3 months, 3 patients developed anti-IFN-alpha antibodies, of whom 2 showed a long lasting tumour response despite the development of these antibodies. None of 3 patients with tumour progression after an initial treatment response had developed IFN-alpha neutralizing antibodies. In conclusion, a low incidence of anti-IFN-alpha antibodies during treatment with high dose IFN-alpha was found, but the appearance had no detrimental effect on the duration of tumour responses in a small number of patients.

AB - Anti-interferon (IFN)-alpha antibodies were determined in the serum of 28 patients treated with high-dose human recombinant IFN-alpha-2a for AIDS-associated Kaposi's sarcoma. After a median treatment duration of 3 months, 3 patients developed anti-IFN-alpha antibodies, of whom 2 showed a long lasting tumour response despite the development of these antibodies. None of 3 patients with tumour progression after an initial treatment response had developed IFN-alpha neutralizing antibodies. In conclusion, a low incidence of anti-IFN-alpha antibodies during treatment with high dose IFN-alpha was found, but the appearance had no detrimental effect on the duration of tumour responses in a small number of patients.

UR - http://www.scopus.com/inward/record.url?scp=0025369471&partnerID=8YFLogxK

U2 - 10.1177/095646249000100405

DO - 10.1177/095646249000100405

M3 - Article

C2 - 2088534

AN - SCOPUS:0025369471

VL - 1

SP - 256

EP - 258

JO - International Journal of STD and AIDS

JF - International Journal of STD and AIDS

SN - 0956-4624

IS - 4

ER -